Oculis Holding AG Ordinary shares (OCS)
- Headquarters
- United States
- Employees
- 60
- Market Cap
- $677M
About Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
SentiSense also tracks daily options readings for Oculis Holding AG Ordinary shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Oculis Holding AG Ordinary shares stock analysis, sentiment tracking, and market intelligence on SentiSense.